اخبار و اعلانات

 آمار

تعداد نشریات24
تعداد شماره‌ها851
تعداد مقالات7,575
تعداد مشاهده مقاله13,413,708
تعداد دریافت فایل اصل مقاله11,580,438
Mirgayazova, Regina, Khadiullina, Raniya, Gilyazova, Elvina, Davletshin, Damir, Ganeeva, Irina, Zmievskaya, Ekaterina, Chasov, Vitaly, Valiullina, Aygul, Bulatov, Emil. (1404). The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia. , 14(3), 179-198. doi: 10.22099/mbrc.2025.51477.2054
Regina Mirgayazova; Raniya Khadiullina; Elvina Gilyazova; Damir Davletshin; Irina Ganeeva; Ekaterina Zmievskaya; Vitaly Chasov; Aygul Valiullina; Emil Bulatov. "The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia". , 14, 3, 1404, 179-198. doi: 10.22099/mbrc.2025.51477.2054
Mirgayazova, Regina, Khadiullina, Raniya, Gilyazova, Elvina, Davletshin, Damir, Ganeeva, Irina, Zmievskaya, Ekaterina, Chasov, Vitaly, Valiullina, Aygul, Bulatov, Emil. (1404). 'The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia', , 14(3), pp. 179-198. doi: 10.22099/mbrc.2025.51477.2054
Mirgayazova, Regina, Khadiullina, Raniya, Gilyazova, Elvina, Davletshin, Damir, Ganeeva, Irina, Zmievskaya, Ekaterina, Chasov, Vitaly, Valiullina, Aygul, Bulatov, Emil. The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia. , 1404; 14(3): 179-198. doi: 10.22099/mbrc.2025.51477.2054

The importance of TP53 status in cancer therapy: The example of chronic lymphocytic leukemia

Molecular Biology Research Communications
دوره 14، شماره 3، 2025، صفحه 179-198    اصل مقاله (633.45 K)
نوع مقاله: Invited review article
شناسه دیجیتال (DOI): 10.22099/mbrc.2025.51477.2054
نویسندگان
Regina Mirgayazova1؛ Raniya Khadiullina1؛ Elvina Gilyazova1؛ Damir Davletshin1؛ Irina Ganeeva1؛ Ekaterina Zmievskaya1؛ Vitaly Chasov1؛ Aygul Valiullina1؛ Emil Bulatov* 1، 2
1Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia
2Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia
چکیده
The TP53 gene encodes the tumor suppressor protein p53, which plays a critical role in genomic stability and cell cycle regulation. TP53 mutations are prevalent in approximately half of all human malignancies and are associated with poor clinical outcomes, including increased genomic instability, chemoresistance, and reduced survival rates. However, the prognostic and predictive value of TP53 status remains inconsistent across cancer types. Chronic lymphocytic leukemia (CLL) stands out as a disease where TP53 alterations have a well-established clinical significance, influencing treatment decisions and patient prognosis. In CLL, TP53 mutations and 17p deletions are strongly correlated with advanced disease stages, resistance to chemo-immunotherapy, and poor overall survival. The European Research Initiative for CLL (ERIC) has recognized TP53 status as a crucial prognostic biomarker, advocating for its routine assessment in clinical practice. Given the limitations of traditional therapies in TP53-mutated CLL, novel targeted therapies, including BCL2 and BTK inhibitors, as well as CAR-T cell therapy, are being explored to improve patient outcomes. This review provides an in-depth analysis of the evolving role of TP53 status in CLL, with a particular focus on emerging therapeutic strategies, including CAR-T cell therapy, and their potential to overcome TP53-driven treatment resistance.
کلیدواژه‌ها
Chronic lymphocytic leukemia؛ TP53 gene؛ Mutation؛ CAR-T therapy
آمار
تعداد مشاهده مقاله: 477
تعداد دریافت فایل اصل مقاله: 442


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب